Novel therapeutic strategies for patients with triple-negative breast cancer

Jun-Fei Zhang1
Jia Liu1,2
Yu Wang1,2
Bin Zhang1,2
1Affiliated Hospital of Inner Mongolia University for the Nationalities, Tongliao, Inner Mongolia, People’s Republic of China; 2Medicinal Chemistry and Pharmacology Institute, Inner Mongolia University for the Nationalities, Tongliao, Inner Mongolia, People’s Republic of China

Abstract: Triple-negative breast cancer (TNBC) represents a very heterogeneous group of breast diseases. Currently, the backbone of therapy for TNBC is mainly chemotherapy as there are no effective specific targeted agents approved to treat TNBC. Despite initial responses to chemotherapy, resistance frequently and rapidly develops and metastatic TNBC has a poor prognosis. Therefore, new targeted strategies are, accordingly, urgently needed. This article discusses the recent developments in targeted agents explored for TNBC, aiming to offer novel therapeutic strategies that can potentially assist in designing personalized therapeutics in the future as well as provide the basis for further research in an attempt to target TNBC.

Keywords: therapeutic strategies, TNBC, targeted agents

Introduction

Breast cancer (BC) is one of the most common cancers for females and the leading cause of cancer-related death in females globally, with a high incidence rate and mortality.1 “Triple-negative” BC (TNBC) was mentioned for the first time in 2005, and, since then, this term has been appearing in publications.2 TNBC, identified as a clinically important subgroup of BC in the early 2000s and characterized by an especially poor prognosis,3 is an aggressive BC subtype lacking the expression of estrogen receptor (ER) and progesterone receptor and overexpression or gene amplification of human epidermal growth factor receptor 2 (HER2). TNBC accounts for a disproportionate number of deaths from BC, especially among premenopausal African-American and Hispanic women who have younger age, more advanced stage distribution, and higher incidence rates.4–6

Disease dynamics, risk of recurrence, and patterns of metastasis in TNBC are different from other subtypes of BC. The most favorable prognosis of TNBCs is predominantly determined by a good response to (neo)adjuvant chemotherapy (NAC), as defined by a pathological complete response (pCR), as a surrogate end point for long-term outcomes.7,8 Indeed, patients who respond poorly to NAC are significantly correlated with unfavorable prognosis.7 Patients who do not achieve pCR still have a high risk of early relapse in the 2 years following surgery; for instance, distant relapse more often involves extra-skeletal sites than bones, in spite of the use of chemotherapy.9 Unlike other subtypes, there are currently no effective specific targeted agents approved to treat TNBC, and the only option for patients is systemic chemotherapy with its inherent toxicities.10

BC represents a very heterogeneous group of breast diseases, and this heterogeneity has extended beyond the classic divisions of ER, progesterone receptor, and HER2. TNBC constitutes ~10%–20% of all BC cases.6 The term TNBC could also be often called “basal-like (BL) BC”; however, they are not the same. BL BC

Correspondence: Bin Zhang
Medicinal Chemistry and Pharmacology Institute, Inner Mongolia University for the Nationalities, No 1742 Holin He Street, Tongliao, Inner Mongolia, Autonomous Region, 028007, People’s Republic of China
Tel +86 475 831 4245
Email bzh9911@163.com
belongs to a subtype of TNBC and accounts for 47%–88% of all TNBCs.\textsuperscript{11,12} Modern treatment strategies are tailored to molecular subtypes.\textsuperscript{13} To better understand the complexity of TNBC and to develop effective therapeutic strategies against it, more extensive genomic, molecular, and biological analyses of TNBCs in many studies classify it into diverse subtypes. According to TNBCs displaying different gene expression and gene ontologies, Lehmann et al\textsuperscript{11} identified six TNBC subtypes, consisting of two BL (BL1 and BL2), an immunomodulatory, a mesenchymal (MES), an MES stem-like, and a luminal androgen receptor (LAR) subtype, and the distinct subtypes had differential sensitivity to targeted therapies. Subsequently, TNBC using mRNA expression and DNA profiling is defined as four stable TNBC subtypes: LAR, MES, BL immune suppressed, and BL immune activated.\textsuperscript{12} Regardless of identifying TNBC subtypes, subtype-specific molecularly targeted strategies have provided the foundation for more effective treatment.

As of today, TNBC is associated with an observably higher odds of relapse and poorer overall survival (OS) in the first few years after diagnosis, compared with other BC subtypes, despite its usual high chemotherapy sensitivity.\textsuperscript{14} The absence of clinically efficient molecularly targeted therapy is still of great concern in the treatment of patients with TNBC. Predisposition gene mutations, including poly (ADP-ribose) polymerase (PARP),\textsuperscript{15} vascular endothelial growth factor (VEGF),\textsuperscript{16} and epidermal growth factor receptor (EGFR),\textsuperscript{17} especially germline genetic testing of BC type 1 susceptibility protein (BRCA1) and BC type 2 susceptibility protein (BRCA2) mutation, are observed among a large TNBC cohort. BRCA1 and BRCA2 have a clear role for patients with TNBC, and BC in carriers with germline BRCA1 mutations is more likely to be TNBC as opposed to 15%–20% (reflective of the general population) of BRCA2 carriers.\textsuperscript{18–20} The identification of molecular targeted agents will be critical to improving survival in the triple-negative (TN) study population. This review discusses the recent discoveries that have furthered our understanding of TNBC and offers a basis for further research for future treatments.

The target and the treatment of TNBC

Traditional chemotherapy for TNBC

Currently, the response to chemotherapy in patients with TNBC may be good, although there is a lack of options. In a meta-analysis of five adjuvant trials comparing anthracycline-containing regimens with cyclophosphamide, methotrexate, and fluorouracil (CMF), a superiority of anthracycline-containing regimens over CMF has been demonstrated via HER2-negative deriving benefit from anthracyclines.\textsuperscript{21} However, the addition of epirubicin to CMF, in a randomized Phase III study, tends to be more superior than CMF alone in the 5-year disease-free survival and 5-year OS for patients with TNBC.\textsuperscript{22} With regard to the use of taxane-based adjuvant regimens, a meta-analysis of randomized trials has evaluated questions about the efficacy of incorporating taxanes into anthracycline-based regimens in terms of disease-free survival and OS, independently of ER expression for early BC.\textsuperscript{23} Therefore, currently, anthracycline/taxane-based adjuvant regimens tend to be clinically the most appropriate adjuvant therapy for patients with TNBC. Exploratory analysis has showed the efficacy of anthracycline/taxane-based adjuvant regimens in combination with capecitabine treatment in a subset of 202 patients with TNBC enrolled in the FinXX study.\textsuperscript{24} The addition of epothilone B analog ixabepilone to capecitabine, which results in an approximately twofold increase in median progression-free survival (PFS) for TN patients, is being compared with capecitabine alone.\textsuperscript{25} Chemotherapy remains the backbone of therapy for TN disease, especially in the metastatic setting, but continued therapy with chemotherapy is shown to encourage tumor resistance to these agents.

Targeted therapy and novel systemic therapy for TNBC

Despite initial responses to anthracycline/taxane-based adjuvant regimens, TNBCs often recur with chemotherapy-resistant, visceral, and brain metastasis. Therefore, targeted agents that are fundamentally different from these classes of regimens need to be explored in TNBC research. In addition, on the basis of these, patients with TNBC need to be best treated with novel therapeutic alternatives, such as third-generation adjuvant chemotherapy and NAC, for instance.\textsuperscript{26}

PARP inhibitors

DNA frequently harbors diverse lesions, including single-strand breaks, double-strand breaks, and homologous recombination (HR).\textsuperscript{27} The PARPs are a large family of enzymes with diverse functions, some of which are important for the repair of single-strand breaks in DNA via the base excision repair pathway.\textsuperscript{28} BRCA1 or BRCA2 dysfunction resulted in a lack of HR and markedly sensitized cells to inhibition of PARP enzymatic activity.\textsuperscript{29} Inhibiting PARP in HR-deficient cells leads to the accumulation of double-strand breaks, genomic instability, and specific synthetic lethality.\textsuperscript{30}
When some factors, such as chemotherapeutic agents, cause DNA damage, PARP could repair DNA damage and PARP inhibitors might sensitize TNBC to these agents. The role of PARPs in DNA repair prompted the investigation of PARP inhibitors as potential treatments for cancer, a disease in which DNA replication and, therefore, replication errors are prominent features, and deficiencies in DNA repair pathways are common.

PARP inhibitors, targeting DNA repair deficiencies, so far represent a real milestone in the treatment of advanced TNBC with BRCA gene dysfunction. Currently, several PARP inhibitors such as olaparib, veliparib, rucaparib, niraparib, and talazoparib (BMN673) are undergoing clinical development. Olaparib (AZD2281) is a well-tolerated oral PARP inhibitor, which has shown promising monotherapy activity in patients with BRCA1 or BRCA2 mutations who have breast and ovarian cancers. Gelmon et al have shown, for the first time, that olaparib has activity responses in patients with high-grade serous cancer without germline BRCA1 or BRCA2 mutations, which has illustrated that olaparib is a promising therapeutic option for women with these aggressive cancers. In addition, iniparib (BSI-201) failed to possess characteristics typical of PARP inhibitors, but could suppress genes involved in telomere function and nonselectively modified cysteine-containing proteins in tumor cells, which may be a result of blockade of other PARP family members. Compared with iniparib, olaparib was more potent in the inhibition of BC cell growth.

Considering preclinical observations regarding the actions of PARP inhibitors, patients with BRCA mutations are the most investigated population in clinical trials of different PARP inhibitors. The combination treatment of PARP inhibitors and chemotherapy or targeted therapy has more potential advantages for the treatment of TNBC. To date, a few Phase I–III trials (Table 1) have demonstrated the efficacy of PARP inhibitors in patients who have TNBC, in parallel in the metastatic and neoadjuvant settings. As part of the I-Spy 2 trial, the combination of carboplatin and veliparib added to weekly paclitaxel and followed by doxorubicin/cyclophosphamide led to a doubling of the pCR rate in patients with TNBC (from 26% to 52%). A Phase III trial statistics for this combination predicted a probability of success of 90%. Combined treatment with olaparib and either the CDK1 inhibitor (RO-3306) or a pan HER inhibitor (neratinib, afatinib) resulted in superior growth inhibition compared to that obtained with olaparib alone. Although better patient stratification is likely to improve therapeutic outcome, several PARP inhibitor resistance mechanisms in BRCA-associated tumors have been proposed. Long-term treatment with olaparib did result in the development of drug resistance, caused by upregulation of Abcb1a/b genes encoding P-glycoprotein efflux pumps. Indeed, the mechanism of acquired resistance to olaparib could be effectively circumvented by an ideal P-glycoprotein drug efflux pump inhibitor, tariquidar (XR9576). More insight into the mechanisms of PARP inhibitor resistance will therefore be instrumental to develop the most optimal treatment strategies that prevent or counteract resistance to PARP inhibitors.

**Platinum salts**

Platinum salts (cisplatin and carboplatin) are also important DNA-damaging agents with activity in BC, particularly in the TN subgroup. The strong interest in platinum-based therapies derives from the fact that almost all TNBCs belong to the molecular subgroup of BLs according to the Perou classification. Table 2 summarizes the current clinical trials investigating platinum salts in BC. A total of 28 studies (six randomized controlled trials and 22 retrospective or prospective studies) have shown that the pooled pCR rate was 45% when a total of 1,598 patients with TNBC were treated with platinum-based NAC. In randomized trials, pCR rate with NAC containing platinum drugs was significantly increased.

### Table 1 Active large Phase I–III trials of PARP inhibitors in patients with TNBC

<table>
<thead>
<tr>
<th>ClinicalTrials.gov identifier</th>
<th>Population</th>
<th>Therapy</th>
<th>Phase</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT0238622</td>
<td>Advanced TNBC</td>
<td>Olaparib (AZD2281) + AZD5363 (AKT inhibitor)</td>
<td>I</td>
<td>Recruiting*</td>
</tr>
<tr>
<td>NCT0077077</td>
<td>mTNBC</td>
<td>AZD2281 + paclitaxel</td>
<td>I</td>
<td>Active, not recruiting*</td>
</tr>
<tr>
<td>NCT01074970</td>
<td>TNBC with BRCA1/2 mutations</td>
<td>Cisplatin + rucaparib + preoperative chemotherapy</td>
<td>II</td>
<td>Active, not recruiting*</td>
</tr>
<tr>
<td>NCT02032277</td>
<td>Early TNBC</td>
<td>Carboplatin-based NAC + veliparib/placebo</td>
<td>III</td>
<td>Recruiting*</td>
</tr>
<tr>
<td>NCT01204125</td>
<td>TNBC</td>
<td>Iniparib (SAR240550-BSI-201) + paclitaxel</td>
<td>II</td>
<td>Recruiting*</td>
</tr>
<tr>
<td>NCT00938652</td>
<td>mTNBC</td>
<td>BSI-201 + gemcitabine/carboplatin</td>
<td>III</td>
<td>Completed*</td>
</tr>
</tbody>
</table>

**Note:** Recent preclinical and clinical data indicate that iniparib does not possess characteristics typical of PARP inhibitor class.

**Abbreviations:** BRCA, breast cancer susceptibility protein; NAC, neoadjuvant chemotherapy; PARP, poly(ADP-ribose) polymerase; TNBC, triple-negative breast cancer; mTNBC, metastatic TNBC.
in contrast to nonplatinum agents (risk ratio = 1.45; 95% CI, 1.25–1.68; *P* < 0.0001). Compared with non-TN, TNBCs treated with NAC containing cisplatin or carboplatin were associated with a threefold increase in the rate of pCR.52 Olaparib in combination with platinum drugs increased the recurrence-free survival and OS. Therefore, platinum analogs alone or combined with targeted agents such as PARP inhibitors might clinically guide the design of future BRCA1-associated BC trials. Gemcitabine and carboplatin plus iniparib as neoadjuvant therapy improved the clinical benefit rate, median PFS, and median OS versus gemcitabine and carboplatin (GC) alone.53 Gemcitabine and carboplatin plus iniparib in Phase II and III clinical trials were also preoperatively active in early TNBC and led to an increased clinical benefit rate, in contrast to the combination of GC.32,54,55 The addition of carboplatin to taxane–anthracycline chemotherapy plus targeted therapy substantially increased pCRs in patients with stage II–III TNBC.56

### Epidermal growth factor receptor

Most TNBCs were also characterized by overexpression of EGFR, which is correlated with a poor prognosis56 and prompted a series of clinical trials incorporating anti-EGFR-directed therapies (Table 3), but the EGFR inhibitor seldom inhibited this pathway. The TBCRC001 trial has investigated not only cetuximab, a monoclonal anti-EGFR antibody as a single-agent blocked expression of the EGFR pathway alone was uncommon but also cetuximab added to a platinum agent had little activity. However, despite these discouraging results, there were long-lasting responses of >12 months (two even over 2.5 years) in four patients (two in the monotherapy and two in the combination arm). Experimental results from the serial biopsies of 18 patients have shown EGFR pathway activation (81%); however, this pathway could only be inactivated by cetuximab in five patients (38%). Clinical benefit was restricted to these patients.57 Gefitinib, the most effective EGFR inhibitor, efficiently blocked epidermal growth factor (EGF)-stimulated phosphorylation of EGFR, reduced phosphorylation of both MAPK and protein kinase B (AKT), and induced G1 arrest in the TNBC cells. Fortunately, the triple combination of gefitinib, carboxplatin, and docetaxel synergistically enhanced the treatment effect in the TNBC cells.58 Elbaz et al59 have shown, for the first time, that cannabinoids significantly inhibited BC growth and metastasis through novel mechanisms by the inhibition of EGF/EGFR signaling and modulation of the tumor microenvironment, which also

### Table 2

Reported studies evaluating cisplatin or carboplatin for the treatment of patients with TNBC

<table>
<thead>
<tr>
<th>ClinicalTrials.gov identifier</th>
<th>Population</th>
<th>Therapy</th>
<th>Phase</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01930292</td>
<td>BL/claudin-low TNBC</td>
<td>Paclitaxel + carboplatin</td>
<td>I</td>
<td>Active, not recruiting62</td>
</tr>
<tr>
<td>NCT01982448</td>
<td>TNBC</td>
<td>Cisplatin + paclitaxel</td>
<td>II</td>
<td>Recruiting68</td>
</tr>
<tr>
<td>NCT01560663</td>
<td>TNBC</td>
<td>Docetaxel + carboplatin</td>
<td>I</td>
<td>Recruiting69</td>
</tr>
<tr>
<td>NCT02393794</td>
<td>mTNBC</td>
<td>Romidepsin + cisplatin</td>
<td>I/II</td>
<td>Recruiting70</td>
</tr>
<tr>
<td>NCT01216124</td>
<td>Local advanced TNBC</td>
<td>Docetaxel + oxaliplatin</td>
<td>II</td>
<td>Unknown41</td>
</tr>
<tr>
<td>NCT01276769</td>
<td>TNBC</td>
<td>Paclitaxel + carboplatin/epirubicin</td>
<td>II</td>
<td>Unknown42</td>
</tr>
<tr>
<td>NCT01216111</td>
<td>TNBC</td>
<td>Paclitaxel + cisplatin</td>
<td>III</td>
<td>Unknown43</td>
</tr>
<tr>
<td>NCT02445391</td>
<td>BL TNBC</td>
<td>Platinum-based chemotherapy</td>
<td>III</td>
<td>Recruiting44</td>
</tr>
<tr>
<td>NCT00861705</td>
<td>TNBC</td>
<td>Carboplatin + bevacinumb + paclitaxel + doxorubicin + cyclophosphamide</td>
<td>II</td>
<td>Active, not recruiting, has results45</td>
</tr>
</tbody>
</table>

### Table 3

Results from selected trials with EGFR-targeted therapies in patients with TNBC

<table>
<thead>
<tr>
<th>ClinicalTrials.gov identifier</th>
<th>Population</th>
<th>Therapy</th>
<th>Phase</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT00463788</td>
<td>TNBC</td>
<td>Cetuximab + cisplatin</td>
<td>II</td>
<td>Completed, has results70</td>
</tr>
<tr>
<td>NCT00232505</td>
<td>TNBC</td>
<td>Cetuximab + carboplatin</td>
<td>II</td>
<td>Active, not recruiting71</td>
</tr>
<tr>
<td>NCT01097642</td>
<td>TNBC</td>
<td>Cetuximab + ixabepilone</td>
<td>II</td>
<td>Active, not recruiting72</td>
</tr>
<tr>
<td>NCT02158507</td>
<td>mTNBC</td>
<td>Veliparib + lapaatinib</td>
<td>–</td>
<td>Recruiting73</td>
</tr>
<tr>
<td>NCT01732276</td>
<td>mTNBC</td>
<td>Gefitinib</td>
<td>II</td>
<td>Not yet recruiting4</td>
</tr>
<tr>
<td>NCT00894504</td>
<td>mTNBC</td>
<td>Gemcitabine + carboplatin + panitumumab</td>
<td>II</td>
<td>Completed, has results75</td>
</tr>
<tr>
<td>NCT01426880</td>
<td>TNBC</td>
<td>Carboplatin + NAC</td>
<td>II/III</td>
<td>Completed76</td>
</tr>
<tr>
<td>NCT00540358</td>
<td>mTNBC</td>
<td>Gemcitabine/carboplatin + iniparib</td>
<td>II</td>
<td>Completed77</td>
</tr>
</tbody>
</table>

**Abbreviations:** EGFR, epidermal growth factor receptor; NAC, neoadjuvant chemotherapy; TNBC, triple-negative breast cancer; mTNBC, metastatic TNBC.
indicated that cannabidiol is a novel therapeutic option in highly aggressive BC subtypes including TNBC.

**Antiangiogenesis**

TNBC is associated with a significantly higher expression and more frequent amplification of VEGF-A. Bevacizumab, an antiangiogenic monoclonal antibody, has been shown to increase the risk ratio and PFS of patients with human EGFR2-negative metastatic BC when added to first-line chemotherapy in randomized Phase III trial. The addition of either carboplatin or bevacizumab to NAC improved pCR rates, while higher pCR rates did not justify the routine addition of bevacizumab in stage II to III TNBC. The addition of bevacizumab to anthracycline–taxane-based chemotherapy in TNBC increased the pCR rate significantly, and pCR rates were 27.9% without and 39.3% with bevacizumab. In addition, the studies have also shown a significant improvement in pCR, PFS, and OS when bevacizumab was added to NAC versus chemotherapy alone. In brief, combined chemotherapy with anti-VEGF therapy may become the potential to be a significant first-line treatment option.

**Immune checkpoint inhibitors**

Currently, recent studies of tumor lymphocytic immune infiltrates in BC have suggested an improved prognosis associated with increasing levels of tumor-infiltrating lymphocytes (TIL). BC is capable of stimulating the immune system. Furthermore, the intensity of tumor immune response has an effect on the effectiveness of cancer therapy and is correlated with favorable clinical outcome in this disease. It is reported that programmed death 1 ligand 1 (PD-L1), an immune checkpoint, was positively prevalent in TN status and high levels of TILs. Programmed cell death protein 1 (PD-1) is also an immune checkpoint that limits T-cell effector functions within tissues. When PD-L1 binds to PD-1, which is present on the surface of T-cells, the lymphocytes become inactivated. Atezolizumab (MPDL3280A), a monoclonal anti-PD-L1 antibody, was generally well tolerated and demonstrated promising efficacy in pretreated metastatic PD-L1 TNBC. In addition, the preliminary results of a recent study have suggested that in a Phase I clinical trial, single-agent pembrolizumab (MK-3475), a monoclonal anti-PD-1, is a well-tolerated and effective treatment with significant therapeutic activity in a subset of heavily pretreated patients with recurrent/metastatic TNBC (mTNBC). Preliminary results of a combination of atezolizumab plus nab-paclitaxel chemotherapy in mTNBC have been reported, and a Phase III trial in untreated mTNBC cancer as first-line therapy has been opened. Multiple additional immune checkpoint receptors and their ligands such as the cytotoxic T lymphocyte antigen-4 (CTLA-4) are the main targets for blockade. The monoclonal antibody, tremelimumab, which inhibits the CTLA-4 pathway, was evaluated in hormone-positive BC and has shown activity. In GeparSixto and CALGB 40603 trials, it might become clear how best to incorporate platinum into the treatment of early TNBC through biomarkers of TIL that could be evaluated as therapeutic targets. Patients with high TILs, which were highly significant pathologic predictors for anthracycline/taxane-based NAC in TNBC, have obviously improved pCR rates, particularly patients treated with carboplatin. Therefore, immunomodulatory agents might appear to increase response rates to NAC. The immunomodulatory drugs lay the foundation for the development of immune-based therapies in TNBC in assessing the immunogenicity of TNBC, indicating a subset of patients who may benefit from immune therapy.

**PI3K/Akt/mTOR**

An initial analysis of whole genome and transcriptome sequencing of TNBCs has suggested that many of the tumors had co-activation of MAPK and PI3K/AKT pathways. Earlier studies showed combinations via inhibiting the coactivation of these pathways had some excellent responses in some but not all patients who were more concerned in phase I trial. While MES tumors tend to frequently activate KRAS, BRAF, and RAS pathways, some may activate JAK-2/STAT3. The current study has demonstrated that celastrol-induced apoptosis in TNBC cells might be mediated through mitochondrial dysfunction and PI3K/Akt axis, while PI3K/Akt/mTOR inhibitor PF-04691502 and mTOR inhibitor, rapamycin, enhanced the effect of celastrol-induced apoptosis in TNBC cells. However, focusing on therapeutic targets geared toward the most commonly known activated pathways such as P53, MAPK, PI3K/AKT, Jak-2, KRAS, BRAF, and RAS and incorporating gene expression in advanced TNBC treatment.

**Androgen receptor**

It has been shown that androgen receptor (AR)-positive TNBCs represented a distinct BC subgroup with adverse clinical outcome, and AR blockade was regarded as a potential endocrine therapy for these patients with TNBC. The LAR subtypes characterized by AR expression were sensitive to the AR antagonist bicalutamide alone or in combination with PI3K inhibitors.
Other targets

Low thyroid hormone receptor beta (TRβ) expression was associated with enhanced resistance to specific therapeutic regimens such as docetaxel and doxorubicin in TNBC through the increase of cAMP/PKA gene signaling, but TRβ-specific agonists in combination with docetaxel or doxorubicin treatment enhanced the sensitivity of TNBC cells. Down-regulation of IGF1R depending on focal adhesion kinase (FAK) regulated the epithelial-to-mesenchymal transition and suppressed colony formation, migration, and invasion of TNBC via the IGF1R/FAK signaling axis, suggesting that co-targeting of IGF1R and FAK could act as therapy markers for MES TNBCs through the IGF1R/ FAK signaling pathway. The article by Cerqueira et al has addressed that high levels of CIP4 expression promoted metastasis of TNBC, while knockdown of CIP4 led to no overt effect on tumor growth but observably suppressed the incidence of TNBC cell invasion in vitro and tumor metastasis in vivo through EGFR/CIP4/Erk/MMP-2 signaling pathway, which demonstrated that targeting CIP4 will become a poor prognostic marker in TNBC. Tate et al have investigated that the histone deacetylase inhibitor, panobinostat (LBH589), was overtly toxic to TNBC cells in vitro due to G2/M cell cycle arrest and apoptosis, and decreased tumorigenesis in vivo and this was also an apparent partial reversal of epithelial-to-mesenchymal transition evidenced by increased cadherin-1, E-cadherin (CDH1) protein expression, and morphology changes in MDA-MB-231 cells, suggesting panobinostat acted as a promising therapeutic option for aggressive TNBC types. A Phase Ib study first reported that pembrolizumab (MK-3475), a highly selective, humanized IgG4/kappa isotype antibody, could block the PD-1 receptor ligand pathway, thereby reactivating the immune system to eradicate tumors to pretreat patients with recurrent/mTNBC. A retrospective analysis demonstrated that the BRCA1 locus product, BRCA1-IRIS, silencing or inactivation using a novel inhibitory mimetic peptide could sensitize TNBC cells to low paclitaxel concentrations in vitro and in vivo, through inactivating two autocrine signaling loops involving EGFR-1 and EGFR3 that regulated AKT causing survivin degradation and Fork head box O3a (FOXO3a) upregulation. However, BRCA1-IRIS targeting therapy cannot completely eradicate TNBC cells overexpressing BRCA1-IRIS; several inhibitors must be combined, such as ERK1/2, AKT, and/or BRCA1-IRIS inhibitors. These combined therapies allow for a more individualized strategic therapy in the future, as well as provide the basis for further research in an attempt to target TNBC.

Prospect

Due to the rapid social development and the increasing of people’s life pressure, patients in growing numbers were diagnosed with breast cancer. Along with the increase in patients with BC, early treatment and early diagnosis were advocated. Once diagnosed, identification of targeted therapy is of great significance through differences in the genetic profile of primary BC. Moreover, participation in an exercise and diet counseling program would lead to loss of body fat, improved fitness, and quality of life and increase habitual physical activity in survivors of TNBC. In addition, patients with TNBC undergoing breast-conserving therapy had better outcomes than with modified radical mastectomy. Reasonable use of these drugs about the above targeted drugs is increasingly utilized for all BC subtypes, because of their advantages, including higher rates of breast-conserving surgery and the possibility of measuring early in vivo response to systemic treatment.

Conclusion

The targeted therapy drugs could become the main content of research currently and in the future. PARP inhibitors and platinum salts might, in an even better fashion, be incorporated into other drugs for clinical treatment of TNBC.

Acknowledgment

This work was support by the National Natural Science Foundation of China (No 81373573).

Disclosure

The authors report no conflicts of interest in this work.

References


